larsucosterol
·Code: 25HC3S
larsucosterol: developed by 2 companies · 1 clinical trial tracked.
larsucosterol evidence translation
What we can confirm
1 tracked trial
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about larsucosterol, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
HepatitisAlcohol-associated hepatitis (AH)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Bausch Health Companies Inc. (BHC) Hepatitis | Phase 3 |
| DURECT CORP (DRRX) Alcohol-associated hepatitis (AH) | Phase 2 |
Clinical Trials (1)
RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)
Primary endpoint: Transplant Free Survival up to Day 90
InterventionalRandomizeddouble350 targetStarted 2026-01Completion 2028-0250 sites · United StatesBausch Health Americas, Inc.
Frequently asked questions
Who is developing larsucosterol?
larsucosterol is being developed by Bausch Health Companies Inc., DURECT CORP.
How many clinical trials involve larsucosterol?
BioSniper tracks 1 clinical trial involving larsucosterol.